ICLUSIG
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ICLUSIG (ICLUSIG).
Ponatinib is a multi-targeted tyrosine kinase inhibitor that inhibits BCR-ABL, including T315I mutant form, and also inhibits VEGFR, PDGFR, FGFR, EPH receptors, and SRC family kinases.
| Metabolism | Primarily metabolized by CYP3A4, with minor contributions from CYP2C8, CYP2D6, and CYP3A5. |
| Excretion | Primarily fecal (91%) as unchanged drug and metabolites; renal elimination accounts for less than 4% of the dose. |
| Half-life | Terminal elimination half-life is approximately 7.5 hours in healthy subjects, supporting twice-daily dosing. |
| Protein binding | Approximately 96% bound to plasma proteins, primarily to albumin and α1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is about 11 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Absolute bioavailability is not established; relative bioavailability after oral administration is approximately 100% compared to an oral solution. |
| Onset of Action | Clinical effect (cytoreduction) is observed within 2 weeks of oral administration. |
| Duration of Action | Duration of cytoreduction persists for approximately 12 hours following each dose, consistent with twice-daily dosing. |
45 mg orally once daily with or without food.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment recommended for mild to moderate renal impairment (eGFR ≥30 mL/min). For severe renal impairment (eGFR <30 mL/min) or end-stage renal disease on dialysis, reduce dose to 30 mg once daily. |
| Liver impairment | No dose adjustment for mild hepatic impairment (Child-Pugh A). For moderate hepatic impairment (Child-Pugh B), reduce dose to 30 mg once daily. For severe hepatic impairment (Child-Pugh C), reduce dose to 15 mg once daily. |
| Pediatric use | Safety and efficacy not established in pediatric patients; no weight-based dosing guidelines available. |
| Geriatric use | No specific dose adjustment required based on age alone, but monitor renal function and hepatic function more frequently due to potential age-related decline. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ICLUSIG (ICLUSIG).
| Breastfeeding | No data are available on the presence of ponatinib in human milk, its effects on the breastfed infant, or its effects on milk production. In lactating rats, ponatinib and its metabolites were excreted in milk at concentrations similar to maternal plasma. Because of the potential for serious adverse reactions in a breastfed infant, advise women not to breastfeed during treatment with Iclusig and for at least 3 weeks after the last dose. M/P ratio is unknown in humans. |
| Teratogenic Risk | Ponatinib is embryo-fetal toxic and teratogenic in animals. Based on its mechanism of action (inhibits multiple tyrosine kinases including VEGF, PDGF, and FGF receptors), there is a potential risk of fetal harm if used during pregnancy, especially during organogenesis in the first trimester. Data in humans are limited; however, in animal studies, ponatinib caused embryo-fetal death, reduced fetal weight, and structural abnormalities at maternal exposures below the human exposure at the recommended clinical dose. Therefore, pregnancy should be avoided during treatment, and women of childbearing potential must use effective contraception during therapy and for at least 3 weeks after the last dose. |
■ FDA Black Box Warning
Vascular occlusion, including fatal arterial and venous thrombosis; heart failure; hepatotoxicity; and pancreatitis.
| Serious Effects |
None known.
| Precautions | Arterial thrombotic events (including fatal myocardial infarction, stroke), venous thromboembolism, heart failure, hepatotoxicity, pancreatitis, hemorrhage, hypertension, cardiac arrhythmias, tumor lysis syndrome, wound healing complications, and fetal harm. |
| Food/Dietary | Grapefruit and grapefruit juice increase ponatinib exposure and should be avoided. Maintain a low-fat diet to reduce risk of pancreatitis. No other significant food interactions reported. |
Loading safety data…
| Fetal Monitoring | For pregnant women exposed to ponatinib, close fetal monitoring with serial ultrasounds is recommended to assess for structural anomalies and growth restriction. Additionally, maternal monitoring for adverse events such as hypertension, pancreatitis, hepatotoxicity, and vascular occlusive events is warranted. Subsequent monitoring for neonatal complications, including thyroid dysfunction and bone growth abnormalities, should be considered. |
| Fertility Effects | Ponatinib may impair fertility in both males and females based on animal studies. In female rats, ponatinib caused disruption of estrous cycles, reduced fertility, and decreased implantation rates at clinically relevant exposures. In male rats, testicular degeneration and reduced sperm counts were observed. Reversibility of these effects is unknown. In humans, the impact on fertility has not been systematically studied, but patients should be informed of the potential for reduced fertility. |
| Clinical Pearls |
| ICLUSIG (ponatinib) is a potent pan-BCR-ABL tyrosine kinase inhibitor with activity against T315I mutant CML. Monitor for arterial thrombotic events, including myocardial infarction and stroke. Baseline and periodic liver function tests are required due to risk of hepatotoxicity. Pancreatitis risk is dose-dependent; hold dose for serum lipase >2x ULN. Use with caution in patients with history of pancreatitis or gallstones. |
| Patient Advice | Take exactly as prescribed; do not stop or change dose without consulting doctor. · Report any signs of blood clots, such as chest pain, shortness of breath, leg swelling, or sudden headache. · Avoid grapefruit and grapefruit juice during treatment due to CYP3A4 interaction. · Use effective contraception during treatment and for at least 2 weeks after last dose. · Notify your doctor immediately if you experience severe abdominal pain, nausea, or vomiting, which may indicate pancreatitis. · Have regular blood tests to monitor liver and pancreas function. |